NZ725131A - Tubulysin derivatives - Google Patents
Tubulysin derivativesInfo
- Publication number
- NZ725131A NZ725131A NZ725131A NZ72513115A NZ725131A NZ 725131 A NZ725131 A NZ 725131A NZ 725131 A NZ725131 A NZ 725131A NZ 72513115 A NZ72513115 A NZ 72513115A NZ 725131 A NZ725131 A NZ 725131A
- Authority
- NZ
- New Zealand
- Prior art keywords
- tubulysin
- formula
- derivatives
- tubulysin derivatives
- conjugates
- Prior art date
Links
- DLKUYSQUHXBYPB-NSSHGSRYSA-N (2s,4r)-4-[[2-[(1r,3r)-1-acetyloxy-4-methyl-3-[3-methylbutanoyloxymethyl-[(2s,3s)-3-methyl-2-[[(2r)-1-methylpiperidine-2-carbonyl]amino]pentanoyl]amino]pentyl]-1,3-thiazole-4-carbonyl]amino]-2-methyl-5-(4-methylphenyl)pentanoic acid Chemical class N([C@@H]([C@@H](C)CC)C(=O)N(COC(=O)CC(C)C)[C@H](C[C@@H](OC(C)=O)C=1SC=C(N=1)C(=O)N[C@H](C[C@H](C)C(O)=O)CC=1C=CC(C)=CC=1)C(C)C)C(=O)[C@H]1CCCCN1C DLKUYSQUHXBYPB-NSSHGSRYSA-N 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 239000002254 cytotoxic agent Substances 0.000 abstract 1
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N dihydromaleimide Natural products O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 150000003053 piperidines Chemical class 0.000 abstract 1
- 229960002317 succinimide Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 229930184737 tubulysin Natural products 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0212—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -N-C-N-C(=0)-, e.g. retro-inverso peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461978460P | 2014-04-11 | 2014-04-11 | |
| PCT/US2015/025235 WO2015157594A1 (en) | 2014-04-11 | 2015-04-10 | Tubulysin derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ725131A true NZ725131A (en) | 2018-03-23 |
Family
ID=54264545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ725131A NZ725131A (en) | 2014-04-11 | 2015-04-10 | Tubulysin derivatives |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9427479B2 (OSRAM) |
| EP (1) | EP3129362A4 (OSRAM) |
| JP (1) | JP2017510661A (OSRAM) |
| KR (1) | KR20160142392A (OSRAM) |
| CN (1) | CN106458942A (OSRAM) |
| AR (1) | AR100006A1 (OSRAM) |
| AU (1) | AU2015243379B2 (OSRAM) |
| CA (1) | CA2945318A1 (OSRAM) |
| CL (1) | CL2016002548A1 (OSRAM) |
| EA (1) | EA032203B1 (OSRAM) |
| IL (1) | IL247822A0 (OSRAM) |
| MA (1) | MA39862A (OSRAM) |
| MX (1) | MX2016013373A (OSRAM) |
| NZ (1) | NZ725131A (OSRAM) |
| PH (1) | PH12016501995A1 (OSRAM) |
| SG (1) | SG11201608203RA (OSRAM) |
| TW (1) | TW201625662A (OSRAM) |
| UY (1) | UY36075A (OSRAM) |
| WO (1) | WO2015157594A1 (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3129055B1 (en) | 2014-04-11 | 2020-07-01 | MedImmune, LLC | Bispecific her2 antibodies |
| TW201625662A (zh) * | 2014-04-11 | 2016-07-16 | 麥迪紐有限責任公司 | 妥布賴森（ｔｕｂｕｌｙｓｉｎ）衍生物 |
| PE20180355A1 (es) | 2015-02-25 | 2018-02-21 | Univ Rice William M | Desacetoxitubulisina h y analogos de esta |
| HRP20200882T1 (hr) | 2015-11-10 | 2020-09-04 | Medimmune, Llc | Vezujuće molekule specifične za asct2 i njihova uporaba |
| SG11201804268RA (en) | 2015-12-04 | 2018-06-28 | Seattle Genetics Inc | Conjugates of quaternized tubulysin compounds |
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| CA3012960A1 (en) * | 2016-02-01 | 2017-08-10 | Pfizer Inc. | Tubulysin analogs and methods for their preparation |
| MY198114A (en) | 2016-04-15 | 2023-08-04 | Macrogenics Inc | Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof |
| JP2019534882A (ja) | 2016-10-11 | 2019-12-05 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | 免疫介在性療法薬を有する抗体−薬物コンジュゲート |
| WO2019025983A1 (en) | 2017-08-01 | 2019-02-07 | Medimmune, Llc | CONJUGATED MONOCLONAL ANTIBODY-MEDICINE DIRECTED AGAINST BCMA |
| SG11202004801WA (en) | 2017-12-31 | 2020-06-29 | Hangzhou Dac Biotech Co Ltd | A conjugate of a tubulysin analog with branched linkers |
| CN109456212A (zh) * | 2018-12-03 | 2019-03-12 | 康化（上海）新药研发有限公司 | 一种沙库比曲中间体的合成方法 |
| EP3898651A2 (en) | 2018-12-21 | 2021-10-27 | Regeneron Pharmaceuticals, Inc. | Tubulysins and protein-tubulysin conjugates |
| TWI753252B (zh) * | 2019-05-03 | 2022-01-21 | 中國大陸商杭州多禧生物科技有限公司 | 含支鏈連接體的Ｔｕｂｕｌｙｓｉｎ同系物偶聯物 |
| JP2022539076A (ja) * | 2019-06-24 | 2022-09-07 | ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． | 分岐連結体を有する細胞結合分子と細胞毒性剤との共役体 |
| JP2023533218A (ja) * | 2020-06-24 | 2023-08-02 | レゲネロン ファーマシューティカルス，インコーポレーテッド | ツブリシン及びタンパク質－ツブリシンコンジュゲート |
| IL301041A (en) | 2020-09-11 | 2023-05-01 | Medimmune Ltd | Therapeutic B7-H4 binding molecules |
| CA3237211A1 (en) | 2021-11-10 | 2023-05-19 | Astrazeneca Ab | Antibody molecules and conjugates |
| GB202117928D0 (en) | 2021-12-11 | 2022-01-26 | Cancer Research Tech Ltd | Immunotherapy for cancer |
| KR20250029133A (ko) | 2022-06-27 | 2025-03-04 | 아스트라제네카 아베 | 암 치료를 위한 표피성장인자 수용체 티로신 키나제 억제제를 포함하는 조합물 |
| WO2025078841A2 (en) | 2023-10-11 | 2025-04-17 | Antikor Biopharma Limited | Antibodies, conjugates, and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7064211B2 (en) * | 2002-03-22 | 2006-06-20 | Eisai Co., Ltd. | Hemiasterlin derivatives and uses thereof |
| US20060148014A1 (en) * | 2004-12-09 | 2006-07-06 | Sergei Agoulnik | Tubulin isotype screening in cancer therapy using hemiasterlin analogs |
| IT1394860B1 (it) * | 2009-07-22 | 2012-07-20 | Kemotech S R L | Composti farmaceutici |
| US8394922B2 (en) * | 2009-08-03 | 2013-03-12 | Medarex, Inc. | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof |
| PT3327027T (pt) * | 2011-11-17 | 2021-02-15 | Pfizer | Péptidos citotóxicos e seus conjugados de anticorpos e fármacos |
| BR112014013526A8 (pt) * | 2011-12-05 | 2017-06-13 | Igenica Biotherapeutics Inc | conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados |
| SI2956173T1 (sl) * | 2013-02-14 | 2017-06-30 | Bristol-Myers Squibb Company | Spojine tubulizina, postopki pridobivanja in uporaba |
| TW201625662A (zh) * | 2014-04-11 | 2016-07-16 | 麥迪紐有限責任公司 | 妥布賴森（ｔｕｂｕｌｙｓｉｎ）衍生物 |
| WO2015155345A1 (en) * | 2014-04-11 | 2015-10-15 | Medimmune Limited | Antibodies and antibody-drug conjugates |
| EP3129055B1 (en) * | 2014-04-11 | 2020-07-01 | MedImmune, LLC | Bispecific her2 antibodies |
-
2015
- 2015-04-10 TW TW104111700A patent/TW201625662A/zh unknown
- 2015-04-10 US US14/683,196 patent/US9427479B2/en not_active Expired - Fee Related
- 2015-04-10 AU AU2015243379A patent/AU2015243379B2/en not_active Ceased
- 2015-04-10 CN CN201580031041.XA patent/CN106458942A/zh active Pending
- 2015-04-10 MA MA039862A patent/MA39862A/fr unknown
- 2015-04-10 EP EP15777523.0A patent/EP3129362A4/en not_active Withdrawn
- 2015-04-10 NZ NZ725131A patent/NZ725131A/en not_active IP Right Cessation
- 2015-04-10 UY UY0001036075A patent/UY36075A/es not_active Application Discontinuation
- 2015-04-10 MX MX2016013373A patent/MX2016013373A/es unknown
- 2015-04-10 CA CA2945318A patent/CA2945318A1/en not_active Abandoned
- 2015-04-10 EA EA201691963A patent/EA032203B1/ru not_active IP Right Cessation
- 2015-04-10 JP JP2017504616A patent/JP2017510661A/ja active Pending
- 2015-04-10 AR ARP150101089A patent/AR100006A1/es unknown
- 2015-04-10 KR KR1020167031176A patent/KR20160142392A/ko not_active Withdrawn
- 2015-04-10 WO PCT/US2015/025235 patent/WO2015157594A1/en not_active Ceased
- 2015-04-10 SG SG11201608203RA patent/SG11201608203RA/en unknown
-
2016
- 2016-08-08 US US15/230,918 patent/US10159745B2/en not_active Expired - Fee Related
- 2016-09-14 IL IL247822A patent/IL247822A0/en unknown
- 2016-10-06 CL CL2016002548A patent/CL2016002548A1/es unknown
- 2016-10-07 PH PH12016501995A patent/PH12016501995A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015243379B2 (en) | 2018-02-01 |
| MX2016013373A (es) | 2017-05-02 |
| KR20160142392A (ko) | 2016-12-12 |
| CA2945318A1 (en) | 2015-10-15 |
| MA39862A (fr) | 2017-02-15 |
| EA201691963A1 (ru) | 2017-06-30 |
| TW201625662A (zh) | 2016-07-16 |
| EA032203B1 (ru) | 2019-04-30 |
| WO2015157594A1 (en) | 2015-10-15 |
| US9427479B2 (en) | 2016-08-30 |
| CN106458942A (zh) | 2017-02-22 |
| EP3129362A1 (en) | 2017-02-15 |
| CL2016002548A1 (es) | 2017-02-24 |
| AU2015243379A1 (en) | 2016-11-03 |
| EP3129362A4 (en) | 2017-08-23 |
| PH12016501995A1 (en) | 2017-01-09 |
| US20160339114A1 (en) | 2016-11-24 |
| JP2017510661A (ja) | 2017-04-13 |
| IL247822A0 (en) | 2016-11-30 |
| SG11201608203RA (en) | 2016-10-28 |
| US10159745B2 (en) | 2018-12-25 |
| UY36075A (es) | 2015-10-30 |
| AR100006A1 (es) | 2016-08-31 |
| US20150291657A1 (en) | 2015-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ725131A (en) | Tubulysin derivatives | |
| PH12018500693A1 (en) | Pyrrolobenzodiazepine antibody drug conjugates and methods of use | |
| PH12016501171A1 (en) | Peptidomimetic compounds and antibody-drug conjugates thereof | |
| PH12015500977A1 (en) | Anti-il-13 receptor alpha 2 antibodies and antibody-drug conjugates | |
| MY170719A (en) | Antibody-drug conjugates | |
| MX381017B (es) | Compuestos peptidomiméticos y conjugados anticuerpo-fármaco de estos. | |
| MX2021008334A (es) | Ligadores que modulan la estabilidad para usar con conjugados anticuerpo-farmaco. | |
| PH12014501039B1 (en) | Cytotoxic peptides and antibody drug conjugates thereof | |
| MX2021010550A (es) | Conjugados de anticuerpo-farmaco hidrofilicos. | |
| ECSP16075472A (es) | Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma | |
| MX2016016515A (es) | Derivados de auristatina y conjugados de los mismos. | |
| MX350200B (es) | Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74. | |
| NZ725480A (en) | Anti-ptk7 antibody-drug conjugates | |
| PH12016501411B1 (en) | Bifunctional cytotoxic agents | |
| PE20150892A1 (es) | Anticuerpos anti-notch y conjugados de anticuerpo-farmaco | |
| MX2016007865A (es) | Peptidos citotoxicos y conjugados de los mismos. | |
| MX347893B (es) | Conjugados de farmaco y anticuerpo humano contra factor de tejido. | |
| PH12016502061A1 (en) | Novel antii-rnf43 antibodies and methods of use | |
| EA201790334A1 (ru) | Конъюгаты анти-cdh6 антитела с лекарственным средством | |
| MX375383B (es) | Conjugados de anticuerpo-fármaco e inmunotoxinas. | |
| MX2016016490A (es) | Conjugados de farmaco-anticuerpo anti-receptor de folato alfa (fra) y metodos de uso de los mismos. | |
| EP4424323A3 (en) | Anti-folr1 immunoconjugate dosing regimens | |
| BR112016010051A2 (pt) | ?conjugados de anticorpo-fármaco anti-efna4? | |
| PH12018500014A1 (en) | Total synthesis of shishijimicin a and analogs thereof | |
| EA201892068A1 (ru) | Конъюгаты napi2b-нацеленное антитело-лекарственное средство и способы их применения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 APR 2020 BY CPA GLOBAL Effective date: 20190307 |
|
| LAPS | Patent lapsed |